Publish Date: 
Mon, 05/07/2018 - 21:43

Published information

Daratumumab, bortezomib, and dexamethasone for multiple myeloma.

Palumbo A et al.N Engl J Med 2016

CASTOR study

Daratumumab, lenalidomide, and dexamethasone for multiple myeloma.

Dimopoulos M et al. N Engl J Med 2016

POLLUX study

Progress in myeloma – a monoclonal breakthrough.

Rajkumar S & Kyle R. N Engl J Med 2016

CASTOR and POLLUX review

Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma.

Mateos MV et al. N Engl J Med 2018

 

ALCYONE study

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

Usmani S et al. Blood 2016

 

SIRIUS + GEN501
pooled analysis

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an openlabel, randomised, phase 2 trial.

Lonial S et al. Lancet 2016

 

SIRIUS study

Daratumumab in multiple myeloma.

Rajkumar S et al. Lancet 2016

SIRIUS review

PBS Information

PBS Information:
This product is not listed
on the PBS.

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING (available from http://www.janssen.com.au/Darzalex_PI) Reference: 1. DARZALEX® Product Information. DARZALEX® is a registered trademark of Janssen-Cilag. Further information is available on request from Janssen-Cilag Pty Ltd, ABN 47 000 129 975, 1-5 Khartoum Road, Macquarie Park NSW 2113. Ph: 1800 226 334. CP-57298 DAR0078 Date prepared April 2018.